Masaru Matsuda

Masaru Matsuda has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Arcutis Biotherapeutics, Inc. and Halozyme Therapeutics, Inc. Over a trading history stretching from 4 September 2021 to 16 September 2026, the count stands at 34 filings.

On the open market, the record shows 1 purchase worth €6,246 and 21 sales worth €1.9M. Sales outweigh purchases by €1.9M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 11 share grants and 1 option exercise. 2026 to date brings no purchases and 5 sales.

The newest entry dates from 18 September 2026: an open-market sale of €80k, in Arcutis Biotherapeutics, Inc. The latest purchase dates back some time: it was published 684 days ago, on 3 December 2024. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.